Tag: editas medicine
January 21, 2019
Editas Medicine Announces Publication in Nature Medicine of Data Supporting the Development of EDIT-101
Editas Medicine (Nasdaq:EDIT), a leading genome editing company, today announced the journal Nature Medicine published the comprehensive, pre-clinical data demonstrating the pharmacology...
November 13, 2018
CRISPR Trials to Watch in 2018
CRISPR Cas-9 gene editing is finally in clinical studies. Here's an overview of CRISPR genetics testing trials currently in progress.
June 28, 2018
5 Top NASDAQ Genetic Stocks of Q2 2018
In the final days of Q2 2018, we've profiled the five top NASDAQ genetic stocks year-to-date. Here's a look at...
April 29, 2018
5 Top Weekly NASDAQ Biotech Stocks: Eleven Biotherapeutics Up 45 Percent
Eleven Biotherapeutics, EyePoint Pharmaceuticals, Avid Bioservices, Cerecor and Celldex were last week's top gainers on the NASDAQ.
April 1, 2018
5 Top NASDAQ Biotech Stocks: Cardiome on Top
Cardiome, Avid, XBiotech, Fennec and Compugen were last week's five top-gaining NASDAQ biotech stocks. See what moved their share prices. March 27, 2018
5 Top NASDAQ Biotech Stocks of Q1 2018
The biotech industry is a unique intersection of companies. Here's a look at the top-gaining biotech companies on the NASDAQ... March 18, 2018